Jilin Aodong Pharmaceutical Group Co., Ltd. (SHE:000623)
China · Delayed Price · Currency is CNY 18.49
+0.05 (0.27%)
Sep 4, 2026, 3:04 PM CST
SHE:000623 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 21,677 | 22,897 | 20,653 | 17,098 | 17,020 | 21,034 | |
Market Cap Growth | -3.14% | 10.86% | 20.79% | 0.46% | -19.09% | 10.96% |
Enterprise Value | 21,221 | 22,283 | 20,126 | 16,961 | 16,158 | 19,596 |
Last Close Price | 18.49 | 19.21 | 16.52 | 13.68 | 13.29 | 16.06 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 6.85 | 9.56 | 13.31 | 11.71 | 9.56 | 11.81 |
Forward PE | - | 7.00 | 8.05 | 8.02 | 24.03 | 24.03 |
PS Ratio | 9.68 | 9.81 | 7.91 | 4.96 | 5.93 | 9.13 |
PB Ratio | 0.67 | 0.74 | 0.71 | 0.62 | 0.65 | 0.84 |
P/TBV Ratio | 0.69 | 0.76 | 0.72 | 0.64 | 0.66 | 0.86 |
P/FCF Ratio | 102.95 | 159.22 | - | - | 111.32 | 1821.95 |
P/OCF Ratio | 69.26 | 84.10 | 347.21 | 251.22 | 40.15 | 64.75 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 9.47 | 9.54 | 7.71 | 4.92 | 5.63 | 8.51 |
EV/EBITDA Ratio | - | 859.61 | 431.72 | 49.91 | 49.49 | 97.79 |
EV/EBIT Ratio | - | - | - | 126.08 | 124.38 | 3339.39 |
EV/FCF Ratio | 100.78 | 154.95 | - | - | 105.68 | 1697.40 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.07 | 0.07 | 0.08 | 0.11 | 0.11 | 0.10 |
Debt / EBITDA Ratio | 38.27 | 46.36 | 30.89 | 8.23 | 8.41 | 12.45 |
Debt / FCF Ratio | 10.64 | 15.57 | - | - | 19.56 | 226.58 |
Net Debt / Equity Ratio | -0.02 | -0.02 | -0.01 | -0.01 | -0.03 | -0.08 |
Net Debt / EBITDA Ratio | -15.57 | -27.93 | -8.28 | -1.02 | -2.68 | -10.08 |
Net Debt / FCF Ratio | -3.20 | -5.03 | 1.80 | 0.99 | -5.73 | -174.93 |
Asset Turnover | 0.06 | 0.07 | 0.08 | 0.11 | 0.10 | 0.08 |
Inventory Turnover | 1.43 | 1.46 | 1.77 | 2.02 | 1.93 | 1.95 |
Quick Ratio | 1.38 | 1.98 | 1.57 | 1.08 | 2.25 | 3.89 |
Current Ratio | 1.65 | 2.40 | 1.96 | 1.29 | 2.70 | 4.35 |
Return on Equity (ROE) | 10.03% | 7.85% | 5.35% | 5.37% | 7.01% | 7.29% |
Return on Assets (ROA) | -0.25% | -0.31% | -0.31% | 0.27% | 0.27% | 0.01% |
Return on Invested Capital (ROIC) | -0.45% | -0.55% | -0.57% | 0.49% | 0.54% | 0.03% |
Return on Capital Employed (ROCE) | -0.40% | -0.50% | -0.50% | 0.50% | 0.40% | 0.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 14.59% | 10.46% | 7.51% | 8.54% | 10.46% | 8.46% |
FCF Yield | 0.97% | 0.63% | -1.04% | -2.06% | 0.90% | 0.06% |
Dividend Yield | 2.71% | 2.60% | 3.03% | 4.38% | 2.26% | 1.87% |
Payout Ratio | 20.46% | 27.10% | 68.33% | 27.44% | 21.21% | 14.36% |
Buyback Yield / Dilution | 0.99% | 0.34% | 9.08% | 0.46% | -3.36% | 1.39% |
Total Shareholder Return | 3.70% | 2.94% | 12.11% | 4.84% | -1.10% | 3.26% |